Corbus Pharmaceuticals Holdings (CRBP) Operating Income (2013 - 2025)

Corbus Pharmaceuticals Holdings' Operating Income history runs 13 years deep, the most recent figure standing at -$24.4 million for Q3 2025.

• On a quarterly basis, Operating Income fell 57.48% year-over-year to -$24.4 million in Q3 2025; TTM through Sep 2025 was -$19.6 million, a 44.78% increase from a year earlier, with the FY2024 full-year figure at $6.3 million, up 114.0% from the prior year.
• Operating Income slipped to -$24.4 million in Q3 2025 per CRBP's latest filing, from $1.3 million in the prior quarter.
• Across five years, Operating Income topped out at $1.8 million in Q4 2024 and bottomed at -$24.4 million in Q3 2025.
• The 5-year median for Operating Income is -$10.1 million (2023), against an average of -$9.8 million.
• Across the five-year window, Operating Income slumped 103.08% in 2023 and surged 117.62% in 2024, its largest moves.
• Year by year, Operating Income stood at -$10.0 million in 2021, then retreated by 7.99% to -$10.8 million in 2022, then gained by 6.42% to -$10.1 million in 2023, then surged by 117.62% to $1.8 million in 2024, then plunged by 1471.74% to -$24.4 million in 2025.
• Per Business Quant, the three latest CRBP Operating Income figures stand at -$24.4 million (Q3 2025), $1.3 million (Q2 2025), and $1.7 million (Q1 2025).